James Webb telescope spots earliest black hole in the known universe, looking 'as far back as you can practically go'
Scientists using the James Webb Space Telescope (JWST) have identified the earliest black hole found thus far, dating back to more than 13 billion years ago.
The black hole and its home galaxy, together dubbed CAPERS-LRD-z9, existed just 500 million years after the Big Bang. Its properties could help researchers understand what the universe was like in that elusive early era, according to a study published August 6 in the Astrophysical Journal Letters.
"When looking for black holes, this is about as far back as you can practically go," study coauthor Anthony Taylor, an astronomer at the University of Texas, Austin, said in a statement. "We're really pushing the boundaries of what current technology can detect."
CAPERS-LRD-z9 is a type of galaxy called a "Little Red Dot," so named because they're small (as galaxies go) and appear to emit red light when observed with JWST's powerful infrared sensors. Little Red Dots shine brightly, which might suggest they contain a lot of stars — except they formed in the early universe, when an abundance of stars was unlikely, according to current leading theories of cosmology.
"The discovery of Little Red Dots was a major surprise from early JWST data, as they looked nothing like galaxies seen with the Hubble Space Telescope," study coauthor Steven Finkelstein, an astronomer at UT Austin, said in the statement. "Now, we're in the process of figuring out what they're like and how they came to be."
To better understand the nature of CAPERS-LRD-z9 and Little Red Dots like it, researchers investigated the galaxy with the JWST. The team found a distinct pattern of wavelengths of light created when fast-moving gas falls into a black hole. Though astronomers have found a few objects farther away than CAPERS-LRD-z9 that might be black holes, this pattern makes CAPERS-LRD-z9 the earliest confirmed black hole to date and suggests that black holes might lie at the center of other Little Red Dots.
Related: James Webb telescope captures one of the deepest-ever views of the universe — Space photo of the week
The black hole at the center of CAPERS-LRD-z9 is pretty hefty. It's some 38 million times more massive than the sun or about 10 times more massive than Sagittarius A*, the supermassive black hole at the center of the Milky Way — though there's considerable wiggle room in that estimate. The scientists also think that the black hole has as much mass as about 5% of all the stars in its galaxy put together, a ratio far exceeding that of modern galaxies.
"This adds to growing evidence that early black holes grew much faster than we thought possible," Finkelstein said. "Or they started out far more massive than our models predict."
RELATED STORIES
—Scientists detect most massive black hole merger ever — and it birthed a monster 225 times as massive as the sun
—Black holes may obey the laws of physics after all, new theory suggests
—Behold the first direct image of a supermassive black hole spewing a jet of particles
CAPERS-LRD-z9 could also help explain why Little Red Dots are red. A dense cloud of gas surrounding the black hole could shift any emitted light into longer, redder wavelengths, the researchers predicted.
Further studies of CAPERS-LRD-z9 could offer even more information about black holes and galaxies in the early universe, the scientists wrote in the study.
"This is a good test object for us," Taylor said in the statement. "We haven't been able to study early black hole evolution until recently, and we are excited to see what we can learn from this unique object."
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
16 minutes ago
- New York Times
The Third Rock From Another Sun Shows No Signs of Life So Far
In the search for signs of life on what seemed like a promising little exoplanet, astronomers' hopes have dimmed. Living things, as we understand them, seem to flourish best in an atmosphere like the one on Earth. But scientists who have been using the James Webb Space Telescope to examine the planet known as Trappist-1 d have found no sign of an earthlike atmosphere, according to a study published on Wednesday in The Astrophysical Journal. Exoplanets revolve around stars other than our sun. And the exoplanet in question is the third of seven that orbit Trappist-1, a star some 40 light-years from our place in the Milky Way. It is a red dwarf, so named because this type of star emits reddish light and tends to be small. In the search for life elsewhere in the galaxy, the discovery of the Trappist-1 planetary system was a big deal. Researchers announced in 2017 that the seven planets around Trappist-1 seemed to have excellent potential as hosts for living things. But in the years since, astronomers have not detected habitable atmospheres on the two innermost planets. They are still examining the outer ones. The star Trappist-1, which was named for a telescope in the Atacama Desert of Chile, is just a little bigger than Jupiter. Red dwarves are the most common stars in our galaxy, but this particular star and its planets are a bit easier to study than other known planetary systems. The system is fairly close to Earth, and the seven planets follow a tight, fast orbit. That makes them good candidates for a method of observation called transmission spectroscopy. When light from a star shines through a planet's atmosphere on its way to the Webb telescope, scientists can find clues about the chemical makeup of that atmosphere by determining which wavelengths of light it absorbed. The third world from the Trappist-1 star, a rocky planet, had appeared promising, according to Caroline Piaulet-Ghorayeb, a postdoctoral researcher at the University of Chicago and the study's lead author. But the starlight that passed the exoplanet before reaching the Webb telescope did not appear to have been filtered through the kinds of atmospheric molecules that are essential to life on Earth, like water or carbon dioxide. The research of Dr. Piaulet-Ghorayeb and her team did not completely rule out the possibility of an atmosphere there, she said. But it did suggest that cool red dwarves — or, at least, this cool red dwarf — might be too volatile to support life. 'Maybe that tells us that it's going to be harder than we thought to find atmospheres on these rocky planets,' she added. Astronomers may need to turn their attention to planets that circle brighter stars, like our sun. Those planets are more difficult to observe and will probably require another telescope, said Jacob Bean, an astronomer at the University of Chicago who advises Dr. Piaulet-Ghorayeb but was not involved in the study. 'We still have this burning question: Can life develop elsewhere?' he said. Dr. Piaulet-Ghorayeb agreed that other planets might be better candidates for life than Trappist-1 d, but she was not ready to give up on the exoplanet just yet. 'There are different ways of figuring out whether these planets have atmospheres,' she said. 'Transmission spectroscopy is just one of them.' Based on the results of her study, she said, 'our job is going to be a little bit harder.' 'But it definitely doesn't kill our prospects,' she added. Dr. Bean called the Trappist-1 system 'a fantastic laboratory for studying terrestrial planets around other stars,' and said that the research so far had yielded plenty of interesting data despite the largely negative result of the latest study. 'If we go look, sometimes we come up disappointed,' Dr. Bean said. 'But if we hadn't looked, we wouldn't know. And it's always better to know.'
Yahoo
19 minutes ago
- Yahoo
Ultra-processed foods that fuel colon cancer — and healthy alternatives that may offset the damage
Growing evidence has linked the rise in colon cancer cases to ultra-processed foods that fill our diets. Researchers found tumors are fueled by Inflammatory compounds and a lack of compounds linked to healing. Foods such as leafy greens and fish may help pinpoint disease-fighting molecules to stave off cancer. As colon cancer diagnoses are on the rise in younger people, researchers are discovering that certain foods may help or hurt our odds of developing the disease. A team of scientists from the University of South Florida and Tampa General Hospital Cancer Institute may have found clues in compounds called bioactive lipids, molecules that can increase or decrease inflammation in the body. In a study published late last year, the researchers analyzed more than 100 tumor samples from patients and found that they contained a higher proportion of these inflammation-causing compounds compared with healthy tissue. Previous evidence has linked increased inflammation to diets high in ultra-processed food, such as chips, sausages, packaged desserts, and refined carbs. As processed food takes up a growing share of the American diet (more than half, recent CDC data shows), a growing number of younger people are being diagnosed with colon cancer. It's now the second-leading cause of cancer-related death in the US. But inflammation isn't just a red flag that the body is under stress: tracking it can help doctors and scientists find ways to bolster the immune system against disease, slowing or stopping tumor growth by cutting back on inflammatory compounds and boosting healthy ones. For instance, the research team found that the tumors were lacking in molecules associated with healing and lowering inflammation. One source of these molecules is our diet, which includes foods such as leafy greens and seafood rich in omega-3 fatty acids. Eating more of these gut-friendly foods and fewer packaged meals may help keep inflammation at bay for better health. "If the molecules are coming from processed food products, they directly imbalance the immune system and drive chronic inflammation," Ganesh Halade, a professor at the University of South Florida Health Heart Institute who coauthored the study, said in a press release. "Our bodies are designed to actively resolve inflammation through bioactive lipid compounds derived from the healthy fats, like avocados, that we consume." While people who follow a "clean" diet can still get cancer, understanding the role of food could give us more tools to fight cancer. Fighting cancer with fish oil Cancer is like a "chronic wound that won't heal," Dr. Timothy Yeatman, a professor of surgery at the University of South Florida who's the senior author of the tumor study, said in the release. A daily diet of ultra-processed foods can make it harder for the body to fight off tumors because of the increased inflammation, he said in a press release. In particular, foods that cancer doctors avoid include processed meats and sugary treats, both of which are linked to higher odds of illnesses, including cancer and cardiovascular disease. While it's not news that spinach and seafood are better for you than bacon and doughnuts, zeroing in on the link between food and inflammation unlocks more effective strategies to stave off disease in the future. For example, the Tampa General Hospital Cancer Institute has conducted early trials of a modified form of fish oil with promising results for reducing inflammation. "This has the potential to revolutionize cancer treatment, moving beyond drugs to harness natural healing processes," Yeatman said. "It's a vital step toward addressing chronic inflammation and preventing diseases before they start." For now, one of the best ways to prevent cancer is to catch it early with routine testing. As far as eating your way to better health, evidence suggests your best bet is sticking to mostly whole, unprocessed foods such as veggies, fruits, legumes, lean proteins, and whole grains for a longer, healthier life."This has the potential to revolutionize cancer treatment, moving beyond drugs to harness natural healing processes," Yeatman said. "It's a vital step toward addressing chronic inflammation and preventing diseases before they start." In the meantime, there's evidence that your best bet for a longer, healthier life is sticking to a diet of mostly whole, unprocessed foods such as veggies, fruits, legumes, lean proteins, and whole grains. Read the original article on Business Insider Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Recent Activities: Patient enrollment in the Company's Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63% in the initial randomized portion of the trial. 72% of the enrolled patients have completed all seven cycles. Ropidoxuridine is being reported by treatment sites as well tolerated. Ended the quarter with $4.8 million in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million in June 2025. Completed a reverse stock split in June 2025 as part of strategic Nasdaq compliance initiative. Appointed George Scorsis as the Chairman of the Board of Directors and appointed Christopher Cooper, our current Interim Chief Executive Officer to our Board of Directors. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth. Mr. Cooper has over 27 years of management and finance experience. 'We are encouraged by the progress in our Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment having recently been achieved. Importantly, 72% of enrolled patients have completed all seven cycles with treatment reported as being well-tolerated,' commented Shuttle Pharma's interim Chief Executive Officer, Chris Cooper. 'We are working closely with our primary third-party CRO, Theradex Systems, to continue execution of the clinical trial in combination with leading cancer centers across the U.S. Our goal continues to remain completion of enrollment later this year, with follow-up and data readouts anticipated in 2026.' Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with potential marketing exclusivity upon obtaining FDA approval for treatment of this disease. The Phase 2 clinical trial design initially randomizes 40 patients into two different dose levels of drug, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating increased survival as compared to historical controls. The Phase 2 clinical trial is conducted at Georgetown University Medical Center, Allegheny Health Network (AHN) Cancer Institute, UNC Medical Center, the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, and Miami Cancer Institute, part of Baptist Health South Florida. An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for palliative therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years. More information about the Phase 2 study (NCT06359379) can be found at About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsChris Cooper Interim Chief Executive Officerinfo@ Investor ContactsLytham Partners, LLC602-889-9700shph@ in to access your portfolio
